Eli­jah Cum­mings (D-Md.) asked Valeant to ex­plain price hikes for two heart med­i­ca­tions. Such in­creases were cen­tral to the com­pany’s strat­egy; it bor­rowed heav­ily to buy drugs, then sharply raised prices. In the past month, Valeant dis­closed it was the su

Much of Valeant’s sales growth has come from ag­gres­sive price hikes— which it’s now sworn off—and M&A.

Bloomberg Businessweek (Europe) - - COMPANIES/ INDUSTRIES - −Mark Glass­man

Bill Ack­man

① Lim­ited growth op­tions Re­ly­ing on takeovers, Valeant has spent rel­a­tively lit­tle on re­search and de­vel­op­ment.

Newspapers in English

Newspapers from Bahrain

© PressReader. All rights reserved.